Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc.verified

FOLD

Price:

$10.82

Market Cap:

$3.20B

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on t...[Read more]

Industry

Biotechnology

IPO Date

2007-05-31

Stock Exchange

NASDAQ

Ticker

FOLD

The PE Ratio as of April 2024 (TTM) for Amicus Therapeutics, Inc. (FOLD) is -21.22

According to Amicus Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -21.22. This represents a change of -22.11% compared to the average of -27.24 of the last 4 quarters.

Amicus Therapeutics, Inc. (FOLD) Historical PE Ratio (quarterly & annually)

How has FOLD PE Ratio performed in the past?

The mean historical PE Ratio of Amicus Therapeutics, Inc. over the last ten years is -11.65. The current -21.22 PE Ratio has changed 18.12% with respect to the historical average. Over the past ten years (40 quarters), FOLD's PE Ratio was at its highest in in the March 2014 quarter at -2.09. The PE Ratio was at its lowest in in the September 2023 quarter at -41.67.

Quarterly (TTM)
Annual

Average

-11.65

Median

-8.53

Minimum

-27.63

Maximum

-3.34

Amicus Therapeutics, Inc. (FOLD) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Amicus Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 344.62%

Maximum Annual PE Ratio = -3.34

Minimum Annual Increase = -58.62%

Minimum Annual PE Ratio = -27.63

Quarterly (TTM)
Annual
YearPE RatioChange
2023-27.6385.20%
2022-14.9219.19%
2021-12.52-42.03%
2020-21.59228.58%
2019-6.5728.84%
2018-5.10-34.37%
2017-7.77132.70%
2016-3.34-58.62%
2015-8.07-10.19%
2014-8.99344.62%

Amicus Therapeutics, Inc. (FOLD) Average PE Ratio

How has FOLD PE Ratio performed in the past?

The current PE Ratio of Amicus Therapeutics, Inc. (FOLD) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-18.36

5-year avg

-16.65

10-year avg

-11.65

Amicus Therapeutics, Inc. (FOLD) PE Ratio vs. Peers

How is FOLD’s PE Ratio compared to its peers?

Amicus Therapeutics, Inc.’s PE Ratio is less than Incyte Corporation (19.48), less than Denali Therapeutics Inc. (-15.22), greater than argenx SE (-72.80), less than Harmony Biosciences Holdings, Inc. (13.28), less than Ultragenyx Pharmaceutical Inc. (-5.84), less than Crinetics Pharmaceuticals, Inc. (-13.72), less than Arvinas, Inc. (-5.82), less than Revolution Medicines, Inc. (-12.05), less than Kura Oncology, Inc. (-9.41), less than Mineralys Therapeutics, Inc. (-6.21), less than Legend Biotech Corporation (-16.52), less than Cytokinetics, Incorporated (-12.52), less than Inhibrx, Inc. (-7.64), greater than DICE Therapeutics, Inc. (-23.17), less than Edgewise Therapeutics, Inc. (-10.06), greater than Karuna Therapeutics, Inc. (-29.52), less than Dyne Therapeutics, Inc. (-6.52), less than Mereo BioPharma Group plc (-12.17), less than Blueprint Medicines Corporation (-10.88), less than Agios Pharmaceuticals, Inc. (-4.93), less than Day One Biopharmaceuticals, Inc. (-7.38), less than BioMarin Pharmaceutical Inc. (100.61),

Build a custom stock screener for Amicus Therapeutics, Inc. (FOLD) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Amicus Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Amicus Therapeutics, Inc. (FOLD) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Amicus Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Amicus Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Amicus Therapeutics, Inc. (FOLD)?

What is the highest PE Ratio for Amicus Therapeutics, Inc. (FOLD)?

What is the 3-year average PE Ratio for Amicus Therapeutics, Inc. (FOLD)?

What is the 5-year average PE Ratio for Amicus Therapeutics, Inc. (FOLD)?

How does the current PE Ratio for Amicus Therapeutics, Inc. (FOLD) compare to its historical average?